Novo to Debut Real-World Wegovy vs Resmetirom MASH Data at AASLD 2025
Novo Nordisk will unveil real-world PLATINUM-Truveta data comparing semaglutide 2.4 mg with resmetirom in MASH at AASLD 2025, with results still undisclosed.
Judge Rejects Novo Bid to Block Lilly Obesity Ads as GLP-1 Peptide Battle Escalates
A federal judge denied Novo’s bid to block Lilly’s Wegovy vs Zepbound ads, finding no prescription decline. The ruling reframes competition in the GLP-1 peptide market.